The Broker Innovation Lab celebrates brokers and other benefits stakeholders who have embraced the changing marketplace to position themselves and their business for future success
Alan Goforth is a freelance writer in suburban Kansas City. In addition to freelancing for several publications, he has written a dozen books about sports and other topics.
The pharmacy chain "deleted internal notes about suspicious prescribers" and allowed "millions of opioid pills" to flow illegally out of stores, alleges the Department of Justice.
"The House Oversight and Accountability Committee is shining a light on this issue in the health care system and will continue to examine solutions to make prescription drugs more affordable for all Americans," says Rep. James Comer.
"From war to inflation, global events have affected each of us individually, leaving internal communicators with a tough terrain to navigate," says Gallagher's State of the Sector report.
Although the average retirement account balance rose in the fourth quarter of last year, balances ended the year down from a year earlier – losing nearly one-quarter of their value, according to a new Fidelity report.
The recession will likely be a bump in the road rather than a pothole that disrupts the economy, with the expected wave of baby boomer retirees lessening job cuts, says a chief economist.
New transparency rules are generating vast amounts of pricing information; however, the health care industry is finding that while collecting data is one thing, making sense of it can be something else entirely
Despite differing objectives, increasing transparency requires stakeholders to work together for common good, according to a panel discussion at the recent Self-Insurance Institute of America's (SIIA) Price Transparency Forum in Kansas City.
Benefits advisors and brokerages of all sizes must band together and learn from each other in order to move the industry forward and create meaningful change.
After attorneys general in GOP-states sent letters to several pharmacies, Walgreens is the first to announce that in those states, it will not sell mifepristone, the first of two drugs in the medication abortion process.